Ian Mortimer Sells 16,315 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CEO Ian Mortimer sold 16,315 shares of the firm’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $40.50, for a total transaction of $660,757.50. Following the sale, the chief executive officer now owns 31,302 shares in the company, valued at approximately $1,267,731. The trade was a 34.26 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Ian Mortimer also recently made the following trade(s):

• On Friday, January 24th, Ian Mortimer sold 22,468 shares of Xenon Pharmaceuticals stock. The stock was sold at an average price of $40.20, for a total transaction of $903,213.60.

Xenon Pharmaceuticals Price Performance

NASDAQ:XENE opened at $40.11 on Tuesday. The company has a market cap of $3.06 billion, a price-to-earnings ratio of -14.22 and a beta of 1.20. Xenon Pharmaceuticals Inc. has a 1 year low of $35.53 and a 1 year high of $50.99. The stock’s 50 day simple moving average is $40.20 and its two-hundred day simple moving average is $40.82.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.01. During the same quarter in the prior year, the firm posted ($0.73) earnings per share. As a group, analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.13 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on XENE. Raymond James reaffirmed an “outperform” rating and issued a $50.00 target price on shares of Xenon Pharmaceuticals in a report on Thursday, October 10th. Needham & Company LLC reiterated a “buy” rating and set a $60.00 target price on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Thursday, December 12th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $56.00.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Blue Trust Inc. increased its stake in Xenon Pharmaceuticals by 174.7% during the third quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 641 shares during the last quarter. Avior Wealth Management LLC bought a new position in shares of Xenon Pharmaceuticals during the 4th quarter valued at approximately $101,000. nVerses Capital LLC bought a new position in shares of Xenon Pharmaceuticals during the 3rd quarter valued at approximately $102,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Xenon Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 487 shares during the period. Finally, KBC Group NV lifted its position in Xenon Pharmaceuticals by 39.8% in the fourth quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 780 shares during the last quarter. Institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.